Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 36% Improvement Relative Risk Mortality (b) 48% ICU time -25% Hospitalization time -6% c19zinc.com/alsulaiman.html Favors zinc Favors control
7 June 2021 - Late treatment study
Evaluation of Zinc Sulfate as an Adjunctive Therapy in COVID-19 Critically Ill Patients: a Two Center Propensity-score Matched Study
Al Sulaiman et al., Critical Care, doi:10.1186/s13054-021-03785-1 (preprint 6/7/2021) (Peer Reviewed)
Source   PDF   Share   Tweet
Retrospective 266 ICU patients showing lower mortality with zinc treatment (very close to statistical significance), and higher odds of acute kidney injury. NRC21R/287/07.
risk of death, 36.0% lower, RR 0.64, p = 0.11, treatment 23 of 82 (28.0%), control 32 of 82 (39.0%), NNT 9.1, adjusted per study, in-hospital, PSM, multivariable Cox proportional hazards.
risk of death, 48.0% lower, RR 0.52, p = 0.03, treatment 19 of 82 (23.2%), control 31 of 82 (37.8%), NNT 6.8, adjusted per study, 30 day, PSM, multivariable Cox proportional hazards.
ICU time, 25.0% higher, relative time 1.25, p = 0.28, treatment 82, control 82.
hospitalization time, 6.2% higher, relative time 1.06, p = 0.61, treatment 82, control 82.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Al Sulaiman et al., 6/7/2021, retrospective, propensity score matching, Saudi Arabia, Middle East, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 March, 2021.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit